<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0003233'>Prolonged QT interval</z:mp> is a predictor of cardiovascular mortality </plain></SENT>
<SENT sid="1" pm="."><plain>It indicates delayed repolarization of ventricular myocardium and is considered a precursor of malignant <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> and <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Increased cardiovascular risk (CVR) in the presence of <z:mp ids='MP_0003233'>prolonged QT interval</z:mp>, corrected by heart rate (QTc), is attributed to ventricular electrical instability </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> (CRD) usually die from <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> before reaching the final stage, final <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> (CRD stage V) </plain></SENT>
<SENT sid="4" pm="."><plain>We investigated whether patients with CRD stage III-V have <z:mp ids='MP_0003233'>prolonged QT interval</z:mp>, what are the possible causes of this extension, and whether in this patient population trimetazidine application may affect the reduction in QT prolongation </plain></SENT>
<SENT sid="5" pm="."><plain>Our study showed one quarter of predialysis patients, mostly asymptomatic, to have QT prolongation, thus being at a higher risk of CV events </plain></SENT>
<SENT sid="6" pm="."><plain>Introducing trimetazidine along with standard therapy can reduce the incidence of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo>, and calculation of the QTc index would be a useful and economical method of screening and monitoring high risk patients </plain></SENT>
</text></document>